Trial reportKidney3602026
Effect of Intravenous Iron Dextran on Kidney Outcomes in Acute Kidney Injury with Iron Deficiency: A Randomized Trial.
Trial report in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05960227 (Effect of Intravenous Iron Repletion on Renal Function in Patients With Iron Deficiency and Acute Kidney Injury, Clinical Trial), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Intravenous Iron Repletion on Renal Function in Patients With Iron Deficiency and Acute Kidney Injury, Clinical Trial
Who cites it
1 citing paper in PubMed.
- The Iron Paradox in Acute Kidney Injury.Kidney360 · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
key pointsIron deficiency is common in patients with AKI. It is unknown whether treating iron deficiency in AKI with intravenous iron reduces the risk of major adverse kidney events. In AKI and iron deficiency, intravenous iron did not reduce the risk of major adverse kidney events at 90 days.
backgroundDuring AKI, iron deficiency may contribute to worse clinical outcome by interfering cellular repair. Correcting iron deficiency with intravenous (IV) dextran iron may reduce the risk of major adverse kidney events (MAKEs). We aimed to assess whether IV iron was more efficacious than conventional management for reducing MAKE in patients with AKI-iron deficiency.
methodsIn a phase 2 randomized controlled trial, from July 2022 to September 2024, patients with AKI and iron deficiency (iron levels <13 μ mol/L or a transferrin saturation <20%) were eligible. We randomly assigned 120 patients to the control ( N =62) and intervention groups (single 1200 mg IV dextran iron infusion; N =58). Primary outcome was the risk of MAKE at 90 days (MAKE90). MAKE were defined as death, KRT, or worsening kidney function. Each component of MAKE and hemoglobin were secondary outcomes.
resultsThe primary outcome MAKE90 occurred in 48 patients in the IV iron group and 47 in the control group (82% versus 75%; P = 0.37). Individual components of MAKE were similar in both groups, 36 (62.1%) versus 38 (61.3%) had worsened kidney function, 14 (24.1%) versus 13 (21%) initiated KRT, and mortality was 43.1% and 38.7% in the IV iron and control groups, respectively ( P ≥ 0.05 for all). Hemoglobin values and adverse events did not differ between groups during the study.
conclusionsIn patients with AKI and iron deficiency, a single dose of IV iron, compared with usual care, did not improve clinical outcomes evaluated by MAKE90, the hemoglobin value, but was safe. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ClinicalTrials.gov, ID: NCT05960227 registered September 19, 2022, Institutional Review Board approval 159/22.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.